Recent research has extended the scope of early recognition and prevention of psychosis beyond disease transition to poor outcomes more broadly.
1-5 This is because the clinical high-risk (CHR) state for psychosis, present in 2% to 10% of youth,
6 may be linked with nonpsychotic morbidity encompassing mood, anxiety, and substance use disorders.
3 Moreover, the CHR state frequently entails persistent neurocognitive and functional deficits, which may cause the affected young persons to increasingly lag behind their peers in a critical phase of personal development.
7-9 Prospective research has demonstrated that these deficits, in combination with clinical and sociodemographic risk factors, foreshadow poor clinical outcomes.
9-13 Similarly, adolescents and young adults who experience a first major affective episode are not only at risk for relapse but frequently have persistent functional deficits, depressive symptoms, and reduced quality of life, as is often seen in patients in the CHR state.
14 These shared impairments
6,15 may point to a common neurobiological surrogate predating the disabling outcomes of these conditions. Such a marker of brain pathology could accurately estimate the risk for functional deficits, thus informing risk-adapted preventive interventions in these vulnerable persons.